Tracking

Thursday, 27 February 2020

CCC publication: Lenalidomide, Dexamethasone and Alemtuzumab or Ofatumumab in High-Risk Chronic Lymphocytic Leukaemia: Final Results of the NCRI CLL210 Trial

Citation: Haematologica.  2020, 105(12), 2868-2871. 2020 Feb 13[Online ahead of print]
Author: Andrew R Pettitt, Richard Jackson, Silvia Cicconi, Fotis Polydoros, Christina Yap, James Dodd, Matthew Bickerstaff, Michael Stackpoole, Umair T Khan, Stacey Carruthers, Melanie Oates, Ke Lin, Sarah E Coupland, Geetha Menon, Nagesh Kalakonda, Helen McCarthy, Adrian Bloor, Anna Schuh, Andrew Duncombe, Claire Dearden, Christopher Fegan, Ben Kennedy, Renata Walewska, Scott Marshall, Christopher P Fox, Peter Hillmen
Abstract: Keywords:  Chronic Lymphocytic Leukemia; alemtuzumab; clinical trial; lenalidomide; ofatumumab.

Link to PubMed record